The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 313-327

  McLaughlin, John ^a,b   Houghton, Lesley A ^c  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

5 hydroxytryptamine (5 HT); Chronic constipation; Gastrointestinal physiology; Irritable bowel syndrome (IBS); Partial 5 HT4 receptor agonist; Serotonin; Tegaserod

Indexed keywords

ALOSETRON; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; CISAPRIDE; DIGOXIN; DRUG METABOLITE; ERYTHROMYCIN; LAXATIVE; O NORTEGASEROD; ORAL CONTRACEPTIVE AGENT; PROKINETIC AGENT; PRUCALOPRIDE; RENZAPRIDE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SPASMOLYTIC AGENT; TEGASEROD; THEOPHYLLINE; UNCLASSIFIED DRUG; WARFARIN; GASTROINTESTINAL AGENT; INDOLE DERIVATIVE; SEROTONIN 4 RECEPTOR;

ABDOMINAL PAIN; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDUCED HEADACHE; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSMENORRHEA; DYSPEPSIA; ECG ABNORMALITY; EVIDENCE BASED MEDICINE; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL TRACT FUNCTION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INFLUENZA; INTESTINE ISCHEMIA; IRRITABLE COLON; ISCHEMIC COLITIS; MORTALITY; NAUSEA; NEUROMODULATION; NONHUMAN; PATHOGENESIS; PREDICTION; QT PROLONGATION; REVIEW; RHINOPHARYNGITIS; SEROTONINERGIC SYSTEM; STRUCTURE ACTIVITY RELATION; SUPRAVENTRICULAR TACHYCARDIA; URINARY TRACT INFECTION; BIOAVAILABILITY; DRUG EFFECT; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BIOLOGICAL AVAILABILITY; CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN; SIGNAL TRANSDUCTION;

EID: 33644932182     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.313     Document Type: Review

References (128)

1. MAYER E, COLLINS SC: Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology (2002) 122:2032-2048.
2. DROSSMAN DA, TALLEY NJ, THOMPSON WC et al.: Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut (1999) 45(Suppl. 2):1-81.
3. GERSHON MD: Importance of serotonergic mechanisms in gastrointestinal motility and sensation. In: Irritable bowel syndrome diagnosis and treatment, Camilleri M, Spiller R (Eds), WB Saunders, London, UK (2002):95-115.
4. KIM D-Y, CAMILLERI M: Serotonin: A mediator of the brain-gut connection. Am. J. Gastroenterol. (2000) 95:2698-2709.
5. SPILLER R: Effects of serotonin on intestinal secretion and motility. Curr. Opin. Gastroenterol. (2001) 17:99-103.
6. DE PONTI F: Serotonin Receptor Modulators. In: Pathophysiology of the enteric nervous system. A basis for understanding functional diseases, Spiller R, Grundy D (Eds), Blackwell Publishing Ltd, Oxford, UK (2004):228-247.
7. BLUM I, VERED Y, GRAFF et al.: The influence of meal composition on plasma serotonin and norepinephrine concentrations. Metabolism (1992) 41:137-140.
8. ERSPAMER V: Occurrence of indolealkylamines in nature. In: Handbook of Experimental Pharmacology: 5-Hydroxytryptamine and related indolealkylamines. Erspamer V (Ed), Springer-Verlag, New York (1966):132-181
9. TOH CC: Release of 5-hydroxytryptamine (serotonin) from the dog's gastrointestinal tract. J. Physiol. (1954) 126:248-254.
10. BEARCROFT CP, PERRETT D, FARTHING MJG: Postprandial plasma 5-hydroxytryptamine in diarrhea predominant irritable bowel syndrome: a pilot study. Gut (1998) 42:42-46.
11. HOUGHTON LA, ATKINSON W, WHITAKER RP, WHORWELL PJ, RIMMER MJ: Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhea predominant irritable bowel syndrome. Gut (2003) 52:663-670.
12. READ NW, GWEE KA: The importance of 5-hydroxytryptamine receptors in the gut. Aliment. Pharmacol. Ther. (1994) 62:159-173.
13. MAWE GM, BRANCHEK TA, GERSHON MD: Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. Proc. Natl. Acad. Sci. USA (1986) 83:9799-9803.
14. HOYER D, CLARKE DE, FOZARD JR et al.: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. (1994) 46:157-203.
15. COOKE HJ: Neurotransmitters in neuronal reflexes regulating intestinal secretion. Ann. NY. Acad. Sci. (2000) 915:77-80.
16. 4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn. Schmiedeberg's Arch. Pharmacol. (2001) 363:146-160.
17. 4 agonist in the treatment of irritable bowel syndrome. Expert Opin. Pharmacother. (2002) 3:1211-1218.
18. TONINI M, MESSORI E, FRANCESCHETTI GP et al.: Characterisation of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br. J. Pharmacol. (1994) 113:1-2.
19. 3 receptors are membrane ion channels. Nature (1989) 339:706-709.
20. 4 receptor positively coupled to adenylate cyclase in neurons. Naunyn. Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410.
21. 4 receptors: cloning and expression of new splice variants. Ann. N.Y. Acad. Sci. (1998) 861:49-56
22. JESSELL TM, KELLY DD: Pain and analgesia. 3rd Edn. Principles of Neural Science, Appleton and Lange, Norwalk, Connecticut, USA (1997).
23. MERTZ H: Altered CNS processing of visceral pain in IBS. In: Irritable bowel syndrome diagnosis and treatment, Camilleri M, Spiller R (Eds), WB Saunders, London, UK (2002):55-68.
24. CROWELL MD: Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol. (2004) 141:1285-1293.
25. HOFFMAN B, MEZEY E, BROWNSTEIN M: Cloning of a serotonin transporter affected by antidepressants. Science (1991) 254:579-580.
26. CHEN JJ, ZHISHAN L, PAN H et al.: Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high affinity serotonin transporter (SERT): abnormal intestinal motility and the expression of cation transporters. J. Neurosci. (2001) 21:6348-6361.
27. GLATT CE, TAMPILIC M, CHRISTIE C, DeYOUNG J, FREIMER NB: Re-screening serotonin receptors for genetic variants identifies population and molecular genetic complexity. Am. J. Med. Genet. (2004) 124B:92-100.
28. 4 knockout mice. Gastroenterology (2003) 124:A342, M1267 (Abstract).
29. CHEY WY, JIN HO, LEE MH, SUN SW, LEE KY: Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am. J. Gastroenterol. (2001) 96:1499-1506.
30. SIMREN M, ABRAHAMSSON H, BJORNSSON ES: An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut (2001) 48:21-27.
31. FUKUDO S, NOMURA T, HONGO M: Impact of corticotrophin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut (1998) 42:845-849.
32. MERTZ H, NALIBOFF B, MUNAKATA J et al.: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology (1995) 109:40-52.
33. ATKINSON W, LOCKHART S, WHORWELL PJ, KEEVIL B, HOUGHTON LA: Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology (2006) 130:34-43.
34. COATES MD, MAHONEY CR, LINDEN DR et al.: Molecular defects in mucosal serotonin content and decreased serotonin re-uptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology (2004) 126:1657-1664.
35. YEO A, BOYD P, LUMSDEN S et al.: Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome. Gut (2004) 53:1452-1458.
36. PATA C, ERDAL ME, DERICI E et al.: Serotonin transporter gene polymorphism in irritable bowel syndrome. Am. J. Gastroenterol. (2002) 97:1780-1784.
37. HEILS A, TEUFEL A, PETRI S et al.: Allelic variation of human serotonin transporter gene expression. J. Neurochem. (1996) 66:2621-2624.
38. LITTLE KY, McLAUGHLIN DP, ZHANG L et al.: Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am. J. Psychiatry (1998) 155:207-213.
39. BELLINI M, RAPPELLI L, BLANDIZZI C et al.: Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am. J. Gastroenterol. (2003) 98:2705-2711.
40. BOSE M, NICKOLS C, GREENWALD S, FEAKINS R, PERRETT D, FARTHING M: 5-hydroxytryptamine (5-HT) levels in colonic mucosa in the irritable bowel syndrome (IBS): assessment by high performance liquid chromatography (HPLC). Gut (2001) 48:A57 (Abstract).
41. MIWA J, ECHIZEN H, MATSUEDA K, UMEDA N: Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habit. Digestion (2001) 63:188-194.
42. DUNLOP SP, COLEMAN NS, BLACKSHAW E et al.: Abnormalities of 5-Hydroxytryptamine metabolism in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. (2005) 3:349-357.
43. BAZZOCCHI G, ELLIS J, VILLANUEVA-MEYER J et al.: Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology (1990) 98:686-693.
44. BASSOTTI G, CHISTOLINI F, MARINOZZI G, MORELLI A: Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome. Digestion (2003) 6:178-183.
45. ATKINSON W, LOCKHART SJ, KEEVIL B, WHORWELL PJ, HOUGHTON LA: Exaggerated postprandial colonic motility in irritable bowel syndrome: a role for 5-hydroxytryptamine? Gastroenterology (2005) 128(4 Suppl. 2):681 (Abstract).
46. ZHAO RH, BAIG MK, MACK J, ABRAMSON S, WOODHOUSE S, WEXNER SD: Altered serotonin immunoreactivities in the left colon of patients with colonic inertia. Colorectal Dis. (2002) 4:56-60.
47. LINCOLN J, CROWE R, KAMM MA, BURNSTOCK G, LENNARD-JONES JE: Serotonin and 5-hydroxyindoleacetic acid are increased in the sigmoid colon in severe idiopathic constipation. Gastroenterology (1990) 98:1219-1225.
48. BAIG MK, ZHAO RH, WOODHOUSE SL et al.: Variability in serotonin and enterochromaffin cells in patients with colonic inertia and idiopathic diarrhea as compared to normal controls. Colorectal Dis. (2002) 4:348-354.
49. EL-SALHY M, NORRGARD O, SPINNELL S: Abnormal colonic endocrine cells in patients with idiopathic slow-transit constipation. Scand. J. Gastroenterol. (1999) 34:1007-1011.
50. DUNLOP SP, JENKINS D, NEAL KR et al.: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology (2003) 125:1651-1659.
51. SPILLER R, JENKINS D, THORNLEY JP et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut (2000) 47:804-811.
52. DUNLOP SP, JENKINS D, SPILLER RC: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol. (2003) 98:1578-1583.
53. GWEE KA, LEONG YL, GRAHAM C et al.: The role of psychological and biological factors in postinfective gut dysfunction. Gut (1999) 44:400-406.
54. WHEATCROFT J, WAKELIN D, JENKINS D et al.: Increased enteroendocrine cell numbers in the Trichinella spiralis infected mouse model of post-infectious bowel dysfunction. Gastroenterology (2002) 122:A162 (Abstract).
55. MOSSNER R, DANIEL S, SCHMITT A et al.: Modulation of serotonin transporter function by interleukin-4. Life Sci. (2001) 68:873-880.
56. LINDEN DR, CHEN JX, GERSHON MD et al.: Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am. J. Physiol. (2003) 285:G207-G216.
57. LEA R, HOUGHTON LA, WHORWELL PJ, WHITAKER P: Evidence of increased plasma 5-Hydroxytryptamine (5-HT) concentration following meal ingestion in patients with functional dyspepsia (FD) and its relationship to gender and symptoms. Gastroenterology (2002) 122(4 Suppl. 1):304 (Abstract).
58. VAN NIEUWENHOVEN MA, VALKS SD, SOBEZAK S, RIEDEL WJ, BRUMMER RJ: Acute tryptophan depletion slows gastric emptying in females. Br. J. Nutr. (2004) 91:351-355.
59. LADABAUM U, GLIDDEN D: Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol. Mot. (2002) 14:395-410.
60. TACK J, BROEKAERT D, COULIE B, FISCHLER B, JANSSENS J: Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment. Pharmacol. Ther. (2003) 17:603-608.
61. MERTZ H, FASS R, KODNER A, YAN-GO F, FULLERTON S, MAYER EA: Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am. J. Gastroenterol. (1998) 93:160-165.
62. WHITAKER P, HOUGHTON LA, MADIRA W, LUNEC J: Gender differences and effects of age on 5-hydroxytryptamine (5-HT) turnover: Implications for irritable bowel syndrome. Gastroenterology (2001) 120(5 Suppl. 1):3226 (Abstract).
63. ATKINSON W, HOUGHTON LA, WHORWELL PJ, WHITAKER P: Gender differences in plasma 5-hydroxytryptamine (5-HT) concentration in diarrhea predominant irritable bowel syndrome (d-IBS): Influence of the menstrual cycle. Gastroenterology (2003) 124(4 Suppl. 1):M1639 (Abstract).
64. ATKINSON W, HOUGHTON LA, WHORWELL PJ, WHITAKER P: Sex hormonal status affects meal stimulated plasma 5-hydroxytryptamine (5-HT) levels in female patients with diarrhea predominant irritable bowel syndrome. Gastroenterology (2002) 122(4 Suppl. 1):M1489 (Abstract).
65. BETHEA CL, MIRKES SJ, SHIVELY CA, ADAMS MR: Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol. Psychiatr. (2000) 47:562-576.
66. LU NZ, ESHLEMAN AJ, JANOWSKY A, BETHEA CL: Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution and function in female macaques. Mol. Psychiatr. (2003) 8:353-360.
67. KOLDZIC-ZIVANOVIC N, SEITZ PK, WATSON CS, CUNNINGHAM KA, THOMAS ML: Intracellular signaling involved in oestrogen regulation of serotonin reuptake. Mol. Cell. Endocrinol. (2004) 226:33-42.
68. BETHEA CL, LU NZ, REDDY A, SHLAES T, STREICHER JM, WHITTEMORE SR: Characterisation of reproductive steroid receptors and response to oestrogen in a rat serotonergic cell line. J. Neurosci. (2003) 127:31-41.
69. MULLER-LISSNER SA: Treatment of chronic constipation with cisapride and placebo. Gut (1987) 28:1033-1038.
70. ABELL TL, CAMILLERI M, DIMAGNO EP, HENCH VS, ZINSMEISTER AR, MALAGELADA J-R: Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig. Dis. Sci. (1991) 36:616-620.
71. CAMILLERI M, KcKINZIE S, FOX J et al.: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. (2004) 2:895-904.
72. AHN J, EHRENPREIS ED: Emerging treatments for irritable bowel syndrome. Expert Opin. Pharmacother. (2002) 3:9-21.
73. APPEL-DINGEMANSE S: Clinical pharmacokinetics of tegaserod, a serotonin 5-HT (4) receptor partial agonist with promotile activity. Clin. Pharmacokinet. (2002) 41:1021-1042.
74. TONINI M: 5-Hydroxytryptamine effects in the gut: the 3,4, and 7 receptors. Neurogastroenterol. Motil. (2005) 17:637-642.
75. 2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. (2004) 143:549-560.
76. BUCHHEIT KH, GAMSE R, GIGER R et al.: The serotonin 5-HT4 receptor: 1. Design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem. (1995) 38:2326-2330.
77. BUCHHEIT KH, GAMSE R, GIGER R et al.: The serotonin 5-HT4 receptor: 2. Structure-activity studies of the indole carbazimidamide class of agonists. J. Med. Chem. (1995) 38:2331-2338.
78. APPEL-DINGEMANSE S, LEMARECHAL MO, KUMLE A, HUBERT M, LEGANGNEUX E: Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Br. J. Clin. Pharmacol. (1999) 47:483-491.
79. ZHOU H, KHALILIEH S, LAU H et al.: Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J. Clin. Pharmacol. (1999) 39:911-919.
80. VICKERS AE, ZOLLINGER M, DANNECKER R, TYNES R, HEITZ F, FISCHER V: In-vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab. Dispos. (2001) 29:1269-1276.
81. SWAN SK, ZHOU H, HOROWITZ A et al.: Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects. J. Clin. Pharmacol. (2003) 43:359-364.
82. ZHOU H, HOROWITZ A, LEDFORD PC et al.: The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. J. Clin. Pharmacol. (2001) 41:1131-1139.
83. ZHOU H, KHALILIEH S, SVENDSEN K et al.: Tegaserod co-administration does not alter the pharmacokinetics of theophylline in healthy subjects. J. Clin. Pharmacol. (2001) 41:987-993.
84. LEDFORD P, ON N, LIGUEROS-SAYLAN M et al.: Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Gastroenterology (2000) 118(4 Suppl. 2):5445 (Abstract).
85. JIN JG, FOXX-ORENSTEIN AE, GRIDER JR: Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J. Pharmacol. Exp. Ther. (1999) 288:93-97.
86. 4 receptor agonists initiate the peristaltic reflex in human, rat and guinea pig intestine. Gastroenterology (1998) 115:370-380.
87. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther. (2001) 15:1745-1751.
88. NGUYEN A, CAMILLERI M, KOST LJ, METZGER A, SARR MG, HANSON RB et al.: SDZ HTF 919 stimulates colonic motility and transit in vivo. J. Pharmacol. Exp. Ther. (1997) 280:1270-1276.
89. PRATHER CM, CAMILLERI M, ZINSMEISTER AR, McKINZIE S, THOMFORDE G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 118:463-468.
90. FIORAMONTI J, MILLION M, BUENO L: Investigations on a 5-HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology (1998) 114(4 Pt 2):G3103 (Abstract).
91. TACK J, VOS R, JANSSENS J, SALTER J, JAUFFRET S, VANDEPLASSCHE G: Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment. Pharmacol. Ther. (2003) 18:1031-1037.
92. THUMSHIRN M, FRUEHAUF H, STUTZ B, TOUGAS G, SALTER J, FRIED M: Effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia and healthy controls. Gastroenterology (2005) 128(4 Suppl. 2):A469, T1158 (Abstract).
93. 4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastroenterology (2005) 128(4 Suppl. 2):A94, 628 (Abstract).
94. FISHER RS, THISTLE J, LEMBO A et al.: Tegaserod does not alter fasting or meal induced biliary tract motility. Am. J. Gastroenterol. (2004) 99:1342-1349.
95. 4 receptor-mediated mechanisms in the regulation of colonic hypersensitivity in rats. Gastroenterology (2003) 124(4 Suppl. 1):21 (Abstract).
96. SCHIKOWSKI A, THEWIBEN C, MATHIS C, ROSS H-G, ENCK P: Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motil. (2002) 14:221-227.
97. SUN Y-N, LUO J-Y: Effect of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbersacral spinal cord. World J. Gastroenterol. (2004) 10:1830-1833.
98. JIAO H-M, XIE P-Y: Tegaserod inhibits noxious rectal distension induced responses and limbic c-Fos expression in rats with visceral hypersensitivity. World J. Gastroenterol. (2004) 10:2836-2841.
99. 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment. Pharmacol. Ther. (2003) 17:577-585.
100. REY E, ALVAREZ SANCHEZ A, DIAZ-RUBIO M: Which is the best distension protocol to study rectal sensitivity in the irritable bowel syndrome? Rev. Esp. Enferm. (2002) 94:211-220.
101. 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment. Pharmacol. Ther. (2003) 17:577-585.
102. LESBROS-PANTOFLICKOVA D, MICHETTI P, FRIED M, BELINGER C, BLUM AL: Meta-analysis: The treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (2004) 20:1253-1269.
103. EVANS BW, CLARK WK, MOORE DJ, WHORWELL PJ: Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. (2004) 1:CD003960.
104. TALLEY, NJ: Evaluation of drug treatment in irritable bowel syndrome. Br. J. Clin. Pharmacol. (2003) 56:362-369.
105. SPILLER, RC: Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am. J. Med. (1999) 107:91S-97S.
106. TACK J, MULLER-LISSNER S, BYTZER P et al.: A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut (2005) 54:1707-1713.
107. REILLY MC, BARGHOUT V, McBURNEY CR, NIECKO TE: Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. (2005) 22:373-380.
108. PATRICK D, BARGHOUT V, PECHER E, BUSHNEL D, MCBURNEY C: Tegaserod significantly improves health related QOL and patient satisfaction in patients with IBS-C. Gastroenterology (2005) 128(4 Suppl. 2):A287, M994 (Abstract).
109. SCHNEIDER H, GONCALBES J, BLOCH H: Tegaserod significantly improves QOL and effectively relieves the multiple dysmotility symptoms associated with IBS-C in South African Women. Gastroenterology (2005) 128(4 Suppl. 2):A468, T1157 (Abstract).
110. TOUGAS G, SNAPE WJ Jr, OTTEN MH et al.: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. (2002) 16(10):1701-1708.
111. BOTTOLI I, TOUGAS G, DUNGER-BALDAUF C, EARNEST D, SHETZLINE M: Efficacy of Tegaserod over 12 months in IBS-C patients: Do responders at month 3 still respond at month 12? Gastroenterology (2005) 128(4 Suppl. 2):A463, T1133 (Abstract).
112. KAMM MA, MULLER-LISSNER S, TALLEY NJ et al.: Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am. J. Gastroenterology (2005) 100:362-372.
113. JOHANSON JF, WALD A, TOUGAS G et al.: Tegaserod is effective and well tolerated in chronic constipation: findings from a randomised, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. (2004) 2:796-805.
114. BANH HL, MacLEAN C, TOPP T, HALL R: The use of tegaserod in critically ill patients with impaired gastric motility. Clin. Pharmacol. Ther. (2005) 77:583-586.
115. + channels and drug-acquired long QT syndrome. Therapie (2000) 55:185-193.
116. NOVARTIS PHARMACEUTICALS: data on file.
117. COLE JA, COOK SF, SANDS BE et al.: Occurrence of colon ischemia in relation to irritable bowel syndrome. Am. J. Gastroenterol. (2004) 99(3):486-491.
118. SINGH G, MITHAL A, TRIADAFILOPOULOS: Patients with irritable bowel syndrome have a high-risk of developing ischemic colitis. Gastroenterology (2004) 126:A349 (Abstract).
119. SCOENFELD P: The safety profile of Tegaserod. Aliment Pharmacol. Ther. (2004) 20(Suppl. 7):25-30.
120. GUL H, YILDIZ O, SIMSEK A et al.: Pharmacologic characterization of contractile serotonergic receptors in human isolated mesenteric artery. Cardiovasc. Pharmacol. (2003) 41(2):307-315.
121. NAPOLITANO C, et al.: Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. (2000) 11(6):691-696.
122. MORGANROTH J, RUEGG PC, DUNGER-BALDAUF C et al.: Tegaserod, a 5-hydroxytryptamine Type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am. J. Gastroenterol. (2002) 97(9):2321-2327.
123. BUSTI AJ, MURILLO JR Jr, CRYER B: Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy (2004) 24(4):526-531.
124. HASLER WL, SCHOENFELD P: Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (2003) 17(8):997-1005.
125. SCHOENFELD P: Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials. Aliment. Pharmacol. Ther. (2004) 19(3):263-269.
126. COREMANS G, KERSTENS R, DE PAUW M, STEVENS M: Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion (2003) 67(1-2):82-89.
127. CAMILLERI M, McKINZIE S, FOX J et al.: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. (2004) 2(10):895-904.
128. QUIGLEY E: Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. Nat. Clin. Pract. Gastroenterol. Hepatol. (2005) 2:436-437.